Marshall Schwartz to Disease Models, Animal
This is a "connection" page, showing publications Marshall Schwartz has written about Disease Models, Animal.
Connection Strength
0.238
-
Katz MS, Thatch KA, Schwartz MZ. The effect of hepatocyte growth factor on gene transcription during intestinal adaptation. J Pediatr Surg. 2011 Feb; 46(2):357-65.
Score: 0.071
-
Katz MS, Thatch KA, Schwartz MZ. Dose variation of hepatocyte growth factor and its effects on an animal model of TPN-induced liver injury. J Surg Res. 2010 Oct; 163(2):294-8.
Score: 0.067
-
Kuenzler KA, Pearson PY, Schwartz MZ. Interleukin-11 enhances intestinal absorptive function after ischemia-reperfusion injury. J Pediatr Surg. 2002 Mar; 37(3):457-9.
Score: 0.038
-
Weis VG, Deal AC, Mekkey G, Clouse C, Gaffley M, Whitaker E, Peeler CB, Weis JA, Schwartz MZ, Atala A. Human placental-derived stem cell therapy ameliorates experimental necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol. 2021 04 01; 320(4):G658-G674.
Score: 0.035
-
Thatch KA, Schwartz MZ, Yoo EY, Mendelson KG, Duke DS. Modulation of the inflammatory response and apoptosis using epidermal growth factor and hepatocyte growth factor in a liver injury model: a potential approach to the management and treatment of cholestatic liver disease. J Pediatr Surg. 2008 Dec; 43(12):2169-73.
Score: 0.015
-
Arthur GL, Schwartz MZ, Kuenzler KA, Birbe R. Glucagonlike peptide-2 analogue: a possible new approach in the management of inflammatory bowel disease. J Pediatr Surg. 2004 Mar; 39(3):448-52; discussion 448-52.
Score: 0.011